<DOC>
	<DOCNO>NCT02842086</DOCNO>
	<brief_summary>The primary objective study assess rate HIV-1 seroconversion Men ( MSM ) transgender woman ( TGW ) sex men administer daily emtricitabine/tenofovir alafenamide ( F/TAF ) emtricitabine/tenofovir DF ( F/TDF ) minimum follow-up 48 week least 50 % participant 96 week follow-up .</brief_summary>
	<brief_title>Safety Efficacy Emtricitabine Tenofovir Alafenamide ( F/TAF ) Fixed-Dose Combination Once Daily Pre-Exposure Prophylaxis Men Transgender Women Who Have Sex With Men Are At Risk HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Key Must high risk sexual acquisition HIV HIV1 negative status MSM TGW ( male birth ) least one following : condomless anal intercourse least two unique male partner past 12 week ( partner must either HIVinfected unknown HIV status ) document history syphilis past 24 week document history rectal gonorrhea chlamydia past 24 week Adequate renal function : estimate glomerular filtration rate ≥ 60 mL/min accord CockcroftGault formula Adequate liver hematologic function : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Absolute neutrophil count ≥ 1000/mm^3 ; platelet ≥ 75,000/mm^3 ; hemoglobin ≥ 10 g/dL Key Exclusion Criteria Grade 3 Grade 4 proteinuria glycosuria unexplained clinically manageable . NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>